A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg - 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg - 150mg once daily) and Placebo in Subjects with Major Depressive Disorder.
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2011
At a glance
- Drugs Bupropion; Venlafaxine
- Indications Depression
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 23 May 2011 Planned number of patients changed to 546.
- 23 May 2011 Status changed from not stated to completed.
- 23 May 2011 Last checked against European Clinical Trials record.